Prognostic value of metastatic pattern in colorectal cancer: a multicenter retrospective analysis in a real-life cohort

被引:8
|
作者
Rumpold, H. [1 ]
Kirchweger, P. [1 ,2 ]
Niedersuss-Beke, D. [3 ]
Falch, D. [3 ]
Wundsam, H. [4 ]
Metz-Gercek, S. [5 ]
Piringer, G. [2 ,6 ]
Thaler, J. [6 ]
机构
[1] Ordensklinikum Linz, Gastrointestinal Canc Ctr, Seilerstaette 4, A-4010 Linz, Austria
[2] Johannes Kepler Univ Linz, Med Fac, Linz, Austria
[3] Wilhelminenspital Stadt Wien, Dept Internal Med 1, Vienna, Austria
[4] Ordensklinikum Linz, Dept Gen & Visceral Surg, Linz, Austria
[5] Clin Canc Ctr Upper Austria, Linz, Austria
[6] Hosp Wels Grieskirchen, Dept Internal Med 4, Wels, Austria
关键词
Colorectal cancer; real-life; metastasis; prognosis; treatment; PULMONARY METASTASES; RESECTION;
D O I
10.1080/0284186X.2020.1837945
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Metastatic patterns have been linked with prognosis in colorectal cancer. We aim to determine the distribution of metastases, their dynamics during disease and their prognostic impact for specific clinical treatment scenarios (resection of metastasis and/or systemic treatment, best supportive care). Material and methods 978 patients diagnosed with metastatic colorectal adenocarcinoma treated at three oncological centers from 2006 to 2018 were included. Overall survival was assessed depending on tumor load, distribution of metastases and treatment of the patients. Results Most patients had single site metastasis (n = 684; 69.9%): 398 patients had liver (n = 398; 40.7%) and 103 patients had lung only metastasis (10.6%). The number of organs involved in metastases at diagnosis was highly prognostic (HR 0.77; CI 0.65, 0.90), whereas the additional gain of metastases during progression of the disease was not. The majority of patients (62.9-74.2%) with initial lung, liver or both metastases retained their initial metastatic status. In the overall population, lung only metastases were associated with the most favorable outcome (HR 0.64; CI 0.50, 0.81). This was also observed in patients receiving best supportive care (HR 0.45; CI 0.27, 0.75). Resection of lung only metastases resulted in longer median survival (102.2 months). A relevant survival difference in patients treated by systemic therapy alone was not observed. Lung only metastasis was associated with rectal cancer (p < .001) and RAS-mutation (p = .01); both, lung and liver metastasis were associated with time from diagnosis to first metastasis (p < .001). Conclusion The number of organs involved in metastasis at diagnosis but not the total cumulative number of involved organs is of prognostic relevance in colorectal adenocarcinoma. This prognostic relevant initial metastasis distribution remains unchanged in the majority of patients during the disease. However, the prognostic impact of the metastatic pattern is potentially altered by treatment modality.
引用
收藏
页码:180 / 186
页数:7
相关论文
共 50 条
  • [31] Adherence and safety of regorafenib for patients with metastatic colorectal cancer: observational real-life study
    Del Prete, Salvatore
    Cennamo, Gregorio
    Leo, Luigi
    Montella, Liliana
    Vincenzi, Bruno
    Biglietto, Maria
    Andreozzi, Francesca
    Prudente, Antonella
    Iodice, Patrizia
    Savastano, Clementina
    Nappi, Anna
    Montesarchio, Vincenzo
    Addeo, Raffaele
    FUTURE ONCOLOGY, 2017, 13 (05) : 415 - 423
  • [32] Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort
    Grinda, Thomas
    Joyon, Natacha
    Lusque, Amelie
    Lefevre, Sarah
    Arnould, Laurent
    Penault-Llorca, Frederique
    Macgrogan, Gaetan
    Treilleux, Isabelle
    Vincent-Salomon, Anne
    Haudebourg, Juliette
    Maran-Gonzalez, Aurelie
    Charafe-Jauffret, Emmanuelle
    Courtinard, Coralie
    Franchet, Camille
    Verriele, Veronique
    Brain, Etienne
    Tas, Patrick
    Blanc-Fournier, Cecile
    Leroux, Agnes
    Loussouarn, Delphine
    Berghian, Anca
    Brabencova, Eva
    Ghnassia, Jean Pierre
    Scoazec, Jean-Yves
    Delaloge, Suzette
    Filleron, Thomas
    Lacroix-Triki, Magali
    NPJ BREAST CANCER, 2021, 7 (01)
  • [33] Real-life use of tolvaptan in ADPKD: a retrospective analysis of a large Canadian cohort
    Calvaruso, Luca
    Yau, Kevin
    Akbari, Pedram
    Nasri, Fatemah
    Khowaja, Saima
    Wang, Bill
    Haghighi, Amirreza
    Khalili, Korosh
    Pei, York
    SCIENTIFIC REPORTS, 2023, 13 (01):
  • [34] Clinical outcome predictors for metastatic renal cell carcinoma: a retrospective multicenter real-life case series
    Rizzo, Mimma
    Pezzicoli, Gaetano
    Tibollo, Valentina
    Premoli, Andrea
    Quaglini, Silvana
    BMC CANCER, 2024, 24 (01)
  • [35] Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort
    Thomas Grinda
    Natacha Joyon
    Amélie Lusque
    Sarah Lefèvre
    Laurent Arnould
    Frédérique Penault-Llorca
    Gaëtan Macgrogan
    Isabelle Treilleux
    Anne Vincent-Salomon
    Juliette Haudebourg
    Aurélie Maran-Gonzalez
    Emmanuelle Charafe-Jauffret
    Coralie Courtinard
    Camille Franchet
    Véronique Verriele
    Etienne Brain
    Patrick Tas
    Cécile Blanc-Fournier
    Agnès Leroux
    Delphine Loussouarn
    Anca Berghian
    Eva Brabencova
    Jean Pierre Ghnassia
    Jean-Yves Scoazec
    Suzette Delaloge
    Thomas Filleron
    Magali Lacroix-Triki
    npj Breast Cancer, 7
  • [36] REAL-LIFE USE OF TOLVAPTAN IN ADPKD: A RETROSPECTIVE ANALYSIS OF A LARGE CANADIAN COHORT
    Calvaruso, Luca
    Yau, Kevin
    Akbari, Pedram
    Nasri, Fatemeh
    Deng, Shirley X.
    Khowaja, Saima
    He, Ning
    Haghighi, Amirreza
    Khalili, Korosh
    Pei, York
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 : I221 - I222
  • [37] Real-life use of tolvaptan in ADPKD: a retrospective analysis of a large Canadian cohort
    Luca Calvaruso
    Kevin Yau
    Pedram Akbari
    Fatemah Nasri
    Saima Khowaja
    Bill Wang
    Amirreza Haghighi
    Korosh Khalili
    York Pei
    Scientific Reports, 13 (1)
  • [38] Cetuximab in first-line treatment of metastatic colorectal cancer in a real-life setting: Preliminary results of the EREBUS cohort.
    Smith, Denis
    Rouyer, Magali
    Mitry, Emmanuel
    Monnereau, Alain
    Cunha, Antonio Sa
    Bignon, Emmanuelle
    Le Monies, Alise
    Jove, Jeremy
    Noize, P.
    Moore, Nicholas
    Fourrier-Reglat, Annie
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [39] A multicenter real-life UK study of use of immunotherapeutic agents in metastatic urothelial cancer.
    Das, Prantik
    Sharma, Anand
    Bhandari, Ruchir
    Lim, JunHao
    Ghose, Aruni
    Davies, Jessica
    Nair, Ajith
    Vasdev, Nikhil
    Moldawa, Maja
    Karimi, Ahmad
    Ward, Colin
    Richardson, Alison
    Singh, Sadmeet
    Peracha, Amjad
    Ahmed, Shaista
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [40] The prognostic value of p53 positive in colorectal cancer: A retrospective cohort study
    Wang, Peng
    Liang, Jianwei
    Wang, Zheng
    Hou, Huirong
    Shi, Lei
    Zhou, Zhixiang
    TUMOR BIOLOGY, 2017, 39 (05)